Product/Composition:- | Pancreatin Tablets |
---|---|
Strength:- | 10,000, 25,000, 40,000, 50,000, 80,000 USP units. |
Form:- | Tablets |
Reference Brands:- | Creon(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Pancreatin tablets contain digestive enzymes—amylase, lipase, and protease—that assist in break down carbohydrates, fats, and proteins. They improve nutrient absorption, reduce digestive discomfort, and support recovery in pancreatic insufficiency. Benefits include better digestion, symptom relief, and improved nutritional status for patients with pancreatitis or enzyme deficiencies.
Pancreatin tablets, containing essential digestive enzymes, are approved in the US by the FDA and in the EU via EMA for pancreatic enzyme replacement therapy in pancreatitis and pancreatic insufficiency. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures regional safety, efficacy, and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports swift approval, safe use, and broad availability of pancreatin tablets, helping improve digestion and nutritional health worldwide.